Applications

1718 – PD-L1 (Programmed Death-Ligand 1) immunohistochemistry testing for persistent, recurrent, or metastatic cervical cancer, to determine eligibility for pembrolizumab treatment

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Withdrawn
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Not applicable
  • Outcome Not applicable

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

Immunohistochemistry (IHC) test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab in patients with persistent, recurrent, or metastatic (spread from where it started) carcinoma of the cervix. The test would be undertaken prior to commencement of pembrolizumab in combination with chemotherapy to enable identification of those patients most likely to benefit from treatment.

Type: Investigative technology

Medical condition this application addresses

Cervical cancer is the growth of abnormal cells in the lining of the cervix, which if left untreated will slowly spread out of the cervix and into the surrounding tissue and organs.This is a codependent application with PBAC.

Consultation survey and deadlines

MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.

Meetings to consider this application

  • PASC meeting: Expedited – bypassing PASC
  • ESC meeting: Expedited – bypassing ESC
  • MSAC meeting: Withdrawn